Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
01 July 2024 - 9:00PM
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial
Officer
Zenas BioPharma, a global biopharmaceutical company committed to
becoming a leader in the development and commercialization of
immunology-based therapies, today announced the appointment of
Orlando Oliveira as its Chief Commercial Officer. With a career
spanning nearly 25 years, Mr. Oliveira brings a wealth of
experience building high-performing global commercial teams,
driving revenue growth, and fostering strategic partnerships in the
biotechnology and pharmaceutical industry.
“As we continue to advance multiple mid- to
late-stage clinical development programs, we are thrilled to
welcome Orlando to the Zenas leadership team,” said Joe Farmer,
President and Chief Operating Officer. “His expertise and track
record of building and leading high performing commercial teams
will be instrumental in the establishment of the obexelimab
franchise and achievement of our goal to bring obexelimab to
patients worldwide. We will benefit immensely from Orlando’s broad
commercial knowledge and leadership as Zenas evolves to become an
integrated development and commercial biopharmaceutical
company.”
“I am eager to join the seasoned executive team
Zenas has built, guided by their mission to deliver transformative
immunology-based therapies to patients in need,” said Mr. Oliveira.
“I look forward to working with this team to further develop and
execute the strategies and plans for the eventual commercialization
of obexelimab and to establish Zenas as a leading global
immunology-based development and commercial company.”
Prior to joining Zenas, Mr. Oliveira served as
Senior Vice President & Head of International at Mirati
Therapeutics (acquired by Bristol Meyers Squibb), where he helped
lead and set up the international foundations of the company and
prepared multiple oncology launches, including leading the European
Medicines Agency approval of KRAZATI®. Previously, he served as
Senior Vice President & General Manager International at Agios
Pharmaceuticals (oncology business acquired by Servier), and in the
same capacity at TESARO (acquired by GlaxoSmithKline). Previously,
he served as Vice President Europe & Intercontinental
Operations at Cubist Pharmaceuticals (acquired by Merck). Mr.
Oliveira also held, during more than a decade, numerous roles of
increasing responsibility at Amgen. Mr. Oliveira currently serves
as a Board member at OncoInvent AS, a privately held clinical-stage
radiopharmaceutical company. He obtained a degree in Pharmacy and a
post-graduate degree in Drug and Pharmacy Law from the University
of Coimbra, Portugal.
About Zenas BioPharma
Zenas BioPharma is a clinical-stage global biopharmaceutical
company committed to becoming a leader in the development and
commercialization of immunology-based therapies for patients in
need. With clinical development capabilities and operations
globally, Zenas is advancing a portfolio of potentially
differentiated autoimmune therapeutics in areas of high unmet
medical need. Zenas’ experienced leadership team and network of
business partners drive operational excellence to deliver
potentially transformative therapies to improve the lives of those
facing autoimmune diseases. For more information about Zenas
BioPharma, please visit www.zenasbio.com and follow us on
X at @ZenasBioPharma and LinkedIn.
Investor and Media Contact:Argot
PartnersZenas@argotpartners.com